Glycine receptor modulating antibody predicting treatable stiff-person spectrum disorders
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 30, 2017
- Accepted in final form December 5, 2017
- First Published January 24, 2018.
Author Disclosures
- Shannon R. Hinson, PhD,
- A. Sebastian Lopez-Chiriboga, MD,
- James H. Bower, MD,
- Joseph Y. Matsumoto, MD,
- Anhar Hassan, MBBCh,
- Eati Basal, PhD,
- Vanda A. Lennon, MD, PhD,
- Sean J. Pittock, MD and
- Andrew McKeon, MD
- Shannon R. Hinson, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- A. Sebastian Lopez-Chiriboga, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- James H. Bower, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Abbvie Clinical Study Protocol M15-562
NONE
NONE
Parkinson Disease Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Joseph Y. Matsumoto, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anhar Hassan, MBBCh,
NONE
NONE
NONE
(1) Parkinsonism and Related Disorders, Editorial Board Member, 2016 onwards. No personal compensation.
NONE
NONE
NONE
(1) Bioblast Pharma (January 2017)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Eati Basal, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Vanda A. Lennon, MD, PhD,
NONE
NONE
NONE
NONE
Vanda Lennon receives royalties from RSR/Kronus for sale of aquaporin-4 autoantibody testing kits and for commercial aquaporin-4 autoantibody testing performed outside Mayo Clinic.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01-NS065829,?CNS Demyelinating Autoimmunity Targeting Water Channel Complexes?. Principal Investigator: S.J. Pittock Co-Investigator: V.A. Lennon Years: 2010-2015
NONE
NONE
NONE
1) RSR/Kronus for sale of aquaporin-4 autoantibody testing kits. 2) Non-Mayo sites performing "home brew" diagnostic testing for aquaporin-4 autoantibody.
Dr. Lennon has a potential financial interest in the technologies listed below: "Aquaporin-4 as an aid for cancer diagnosis".
NONE
NONE
NONE
- Sean J. Pittock, MD and
NONE
NONE
NONE
NONE
Dr. Pittock and Mayo Clinic have a financial interest in patents (#12/678,350 filed 2010 and #12/573,942 filed 2008) that relate to functional AQP4/NMO-IgG assays and NMO-IgG as a cancer marker;
NONE
NONE
Dr. Pittock has provided consultation to Alexion Pharmaceuticals and Medimmune but has received no personal fees or personal compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic.
NONE
NONE
NONE
Dr Pittock has received research funding from Grifols, Medimmune and Alexion.
RO1 NS065829-01
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Andrew McKeon, MD
NONE
NONE
NONE
NONE
Patent applications pending: GFAP and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders
NONE
NONE
Grifols Medimmune Euroimmun No personal compensation received for these activities
NONE
NONE
NONE
Medimmune, Inc Euroimmun
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Laboratory Medicine and Pathology (S.R.H., E.B., V.A.L., S.J.P., A.M.), Department of Neurology (A.S.L.-C., J.H.B., J.Y.M., A.H., V.A.L., S.J.P., A.M.), and Department of Immunology (V.A.L.), Mayo Clinic, Rochester, MN.
- Correspondence
Dr. McKeon mckeon.andrew{at}mayo.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Clinical/Scientific Notes
Glycine receptor antibodies in stiff-person syndrome and other GAD-positive CNS disordersHarry Alexopoulos, Sofia Akrivou, Marinos C. Dalakas et al.Neurology, October 30, 2013 -
Clinical/Scientific Notes
Lockjaw in stiff-person syndrome with autoantibodies against glycine receptorsKathrin Doppler, Barbara Schleyer, Christian Geis et al.Neurology - Neuroimmunology Neuroinflammation, December 10, 2015 -
Article
Progressive encephalomyelitis with rigidity and myoclonusA new variant with DPPX antibodiesBettina Balint, Sven Jarius, Simon Nagel et al.Neurology, April 02, 2014 -
Clinical/Scientific Notes
Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomyK. Clerinx, T. Breban, M. Schrooten et al.Neurology, January 17, 2011